Exploratory test to investigate the clinical pregnancy rate between four vaginal progesterones:Lutinus vaginal tablet(300 mg/day), Utrogestan Vaginal Capsule(600 mg/day), Luteum Vaginal Suppository(800 mg/day), Crinone vaginal gel (90 mg/day)

Exploratory test to investigate the clinical pregnancy rate between four vaginal progesterones:Lutinus vaginal tablet(300 mg/day), Utrogestan Vaginal Capsule(600 mg/day), Luteum Vaginal Suppository(800 mg/day), Crinone vaginal gel (90 mg/day) - EXCULL-STUDY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032997

Enrollment

240

Registered

2018-06-14

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Lutinus (3 doses of 100 mg per day) Utrogestan (3 doses of 200 mg per day) Luteum (2 doses of 400 mg per day) Onecrinone (1 dose of 90 mg per day)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients who will undergo the frozen embryo transfer in hormone replacement therapy cycles. 2) Patients who have given written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: Patients related to the contraindication items described in the drug package

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate (CPR), Fetal heartbeat positive rate(FHR) and miscarriage rate (MR).	—

Secondary

Measure	Time frame
serum progesterone	—

Countries

Japan

Contacts

Public ContactREIKO SHIBA

Kinutani Womens Clinic Doctor department

reiko.shiba0703@gmail.com082-247-6399

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026